Editorials

The MAQC consortium's latest study suggests that human error in handling DNA microarray data analysis software could delay the technology's wider adoption in the clinic.

The rise of open source drug R&D in consortia involving big pharma should prompt some biotech companies to re-examine their businesses.

Provenge already looks like the product of a bygone era.

The sheer pace of discovery in genetics is placing companies that pursue an aggressive infringement strategy for gene patents increasingly at odds with innovation.

A consortium of industry, nonprofit institutions and regulators outlines a rolling biomarker qualification process, providing the first clear path for translation of such markers from discovery to preclinical and clinical practice.

Healthcare reform will not only boost biotech investment by massively expanding the US drug market, but also change the dynamics of biotech innovation in the longer term.

To remain competitive in biotech, policymakers should pay more attention to retaining skilled foreign workers than to fixating on illegal immigration.

Criticisms of the response of governments and of the pharmaceutical industry to the threat of the H1N1 epidemic are wide of the mark.

Impractical solutions to European biotech financing don't help anyone.

The biotech brand is in danger of being sullied by the blurring of pharma and biotech boundaries.

Why cloud computing could broaden community access to next-generation sequencing.

The ability to plug and play synthetic genes into minimized genomes promises to transform biological engineering.

Similar to outsourcing in the corporate world, technology incubators are beginning to look beyond their own borders to find technology.

Announcing an initiative to connect commercially oriented academics with their local business community.

As the cost of human genome sequencing plunges and large-scale genome-phenotype studies become possible, society should do more to reward those individuals who choose to disclose their data, despite the risks.

The strategy outlined in the UK's Life Sciences Blueprint is unlikely to address the British biotech sector's woes or help it regain prominence and success.

A universal tagging system that links data sets with the author(s) that generated them is essential to promote data sharing within the proteomics and other research communities.

In contrast to the slow translation of human genome information into medicine, animal genomics is likely to have a rapid and tangible impact on agriculture.

Industry has been warned: US Food and Drug Administration (FDA) approval is no shield against failure-to-warn or product-liability suits.

If there is one thing that the new team at the US Food and Drug Administration should immediately implement, it is a comprehensive, open database of drug-related adverse events.